---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-063955"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:13:14.569009+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Gilead to acquire Arcellx for $115/share plus $5 CVR; implied equity value $7.8B

## Summary
- Per-share consideration: $115 cash at closing + one CVR worth up to $5 contingent on anito-cel cumulative sales exceeding $6B by Dec 31, 2029.
- Gilead gains full control of anito-cel, a BCMA-directed CAR T-cell therapy currently under FDA review with a PDUFA date of Dec 23, 2026.
- Support stockholders (entities affiliated with NEA, SR One, directors, officers) holding ~10.3% of shares have agreed to tender in the offer.
- Transaction is structured as a tender offer followed by a Section 251(h) merger; Arcellx may pay a $260M termination fee under specified circumstances.
- Arcellx will conduct business in ordinary course and is subject to a no-shop restriction prior to the Offer Acceptance Time.

## SEC filing metadata
- accession: 0001193125-26-063955
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000119312526063955/0001193125-26-063955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000119312526063955/d112937d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-063955
- JSON: https://secwatch.observer/filing/0001193125-26-063955.json
- Plain text: https://secwatch.observer/filing/0001193125-26-063955.txt

## Key facts
- Material Agreements
  Arcellx, Inc. entered into Agreement and Plan of Merger with Gilead Sciences, Inc. (effective 2026-02-22).
  - Action: entry
  - Agreement: merger
  - Counterparty: Gilead Sciences, Inc.
  - Effective: 2026-02-22
  source text: On February 22, 2026, Arcellx, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Gilead Sciences, Inc., a Delaware corporation (“ Parent ”), and Ravens Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1786205/000119312526063955/0001193125-26-063955-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.